Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ECCPharm
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
ECCPharm is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages a proprietary structure-based drug design (SBDD) and artificial intelligence (AI) platform to target challenging biological pathways in oncology and immunology. Its lead programs focus on the RAS signaling pathway, including inhibitors for KRAS G12D and KRAS G12C, as well as other high-value targets like SOS1 and SHP2. ECCPharm aims to address significant unmet medical needs in solid tumors and autoimmune diseases through precision medicine.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on ECCPharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECCPharm.